Stock PCSA PROCESSA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Real-time Estimate Cboe BZX
Other stock markets
 02:21:13 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.48 USD -6.33% Intraday chart for Processa Pharmaceuticals, Inc. -17.22% -77.73%
May. 10 Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 30 Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research CI

Evolution of the average Target Price on Processa Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

70eef84f945e6e64ca926074.N3Mj6lTE2102sz_hmsy4AE1euYLfSfarbdeMyZOWVmc.bgVKvRqclA9e3FKDt4_ccgg1idGqB5PGH5vb-dfvLBVPFmuTbfHqGFeeXA~931b0bb40cdfc8656157491a9395620d

Analyst Recommendations on Processa Pharmaceuticals, Inc.

Top Midday Gainers MT
HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target MT
Benchmark Adjusts Price Target on Processa Pharmaceuticals to $4 From $9, Keeps Speculative Buy Rating MT
Oppenheimer Adjusts Processa Pharmaceuticals Price Target to $3 From $5, Maintains Outperform Rating MT
Maxim Adjusts Price Target on Processa Pharmaceuticals to $5 From $9, Maintains Buy Rating MT
Oppenheimer Adjusts Processa Pharmaceuticals' Price Target to $11 From $17, Maintains Outperform Rating MT
Maxim Initiates Processa Pharmaceuticals at Buy with $9 Price Target MT
PROCESSA PHARMACEUTICALS : Oppenheimer Starts Processa Pharmaceuticals at Outperform With $20 Price Target MT
PROCESSA PHARMACEUTICALS : Benchmark Starts Processa Pharmaceuticals at Buy with $15 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.58 USD
Average target price
6 USD
Spread / Average Target
+279.75%
High Price Target
8 USD
Spread / Highest target
+406.33%
Low Price Target
4 USD
Spread / Lowest Target
+153.16%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Processa Pharmaceuticals, Inc.

HC Wainwright
Benchmark Company
Oppenheimer
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PCSA Stock
  4. Consensus Processa Pharmaceuticals, Inc.